LUNG
Pulmonx Corporation NASDAQ Listed Oct 1, 2020$1.27
Mkt Cap $53.6M
52w Low $1.13
5.1% of range
52w High $3.88
50d MA $1.43
200d MA $1.74
P/E (TTM)
-1.0x
EV/EBITDA
-1.4x
P/B
1.0x
Debt/Equity
1.0x
ROE
-99.8%
P/FCF
-2.7x
RSI (14)
—
ATR (14)
—
Beta
0.19
50d MA
$1.43
200d MA
$1.74
Avg Volume
518.9K
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
700 Chesapeake Drive · Redwood City, CA 94063 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | AMC | -0.33 | -0.33 | +0.0% | 1.20 | -1.7% | +6.7% | +12.5% | +10.8% | +5.8% | +7.5% | — |
| Mar 4, 2026 | AMC | -0.39 | -0.25 | +35.9% | 1.44 | +0.7% | +11.8% | +40.3% | +26.4% | +24.3% | +25.0% | — |
| Nov 12, 2025 | AMC | -0.40 | -0.34 | +15.0% | 1.96 | -1.5% | -18.9% | -24.0% | -30.6% | -28.6% | -29.6% | — |
| Jul 30, 2025 | AMC | -0.40 | -0.38 | +5.0% | 3.15 | -36.8% | -41.6% | -48.9% | -47.6% | -47.9% | -48.9% | — |
| Apr 30, 2025 | AMC | -0.37 | -0.36 | +2.7% | 4.83 | +7.9% | -21.9% | -21.9% | -25.9% | -28.8% | -23.8% | — |
| Feb 19, 2025 | AMC | -0.45 | -0.33 | +26.7% | 6.64 | +14.5% | +32.2% | +34.9% | +34.3% | +30.7% | +38.9% | — |
| Oct 30, 2024 | AMC | -0.43 | -0.36 | +16.3% | 6.79 | -0.6% | -8.0% | -7.7% | +4.9% | +4.7% | +13.5% | — |
| Jul 31, 2024 | AMC | -0.41 | -0.39 | +4.9% | 6.91 | +0.1% | -6.1% | -7.5% | -13.6% | -14.2% | -15.2% | — |
| May 1, 2024 | AMC | -0.43 | -0.36 | +16.3% | 7.72 | +29.3% | +21.5% | +27.2% | +20.2% | +23.4% | +14.1% | — |
| Feb 21, 2024 | AMC | -0.39 | -0.36 | +7.7% | 14.50 | -2.1% | -18.2% | -25.4% | -28.3% | -30.2% | -35.4% | — |
| Oct 30, 2023 | AMC | -0.45 | -0.39 | +13.3% | 7.89 | +10.9% | +11.4% | +15.1% | +18.8% | +25.7% | +21.8% | — |
| Aug 2, 2023 | AMC | -0.43 | -0.43 | +0.0% | 13.23 | +5.7% | +0.2% | +0.2% | -3.9% | -8.7% | -15.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | D. Boral Capital | Maintains | Buy → Buy | — | $1.20 | $1.18 | -1.7% | +6.7% | +12.5% | +10.8% | +5.8% | +7.5% |
| Mar 5 | D. Boral Capital | Maintains | Buy → Buy | — | $1.44 | $1.45 | +0.7% | +11.8% | +40.3% | +26.4% | +24.3% | +25.0% |
| Mar 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.44 | $1.45 | +0.7% | +11.8% | +40.3% | +26.4% | +24.3% | +25.0% |
| Feb 20 | D. Boral Capital | Maintains | Buy → Buy | — | $1.42 | $1.43 | +0.7% | +6.3% | +4.2% | +6.3% | +14.8% | +15.5% |
| Nov 13 | D. Boral Capital | Maintains | Buy → Buy | — | $1.96 | $1.93 | -1.5% | -18.9% | -24.0% | -30.6% | -28.6% | -29.6% |
| Oct 28 | Lake Street | Maintains | Buy → Buy | — | $1.56 | $1.88 | +20.5% | +26.9% | +23.1% | +12.8% | +28.2% | +17.3% |
| Oct 28 | D. Boral Capital | Maintains | Buy → Buy | — | $1.56 | $1.88 | +20.5% | +26.9% | +23.1% | +12.8% | +28.2% | +17.3% |
| Sep 8 | D. Boral Capital | Maintains | Buy → Buy | — | $1.74 | $1.72 | -1.1% | -2.3% | -2.9% | -7.5% | -2.9% | -2.3% |
| Aug 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $1.84 | $1.85 | +0.5% | -12.5% | -10.3% | -10.9% | -12.5% | -12.0% |
| Jul 31 | Piper Sandler | Downgrade | Overweight → Neutral | — | $3.15 | $1.99 | -36.8% | -41.6% | -48.9% | -47.6% | -47.9% | -48.9% |
| Jul 31 | Lake Street | Maintains | Buy → Buy | — | $3.15 | $1.99 | -36.8% | -41.6% | -48.9% | -47.6% | -47.9% | -48.9% |
| Jul 31 | Stifel | Maintains | Buy → Buy | — | $3.15 | $1.99 | -36.8% | -41.6% | -48.9% | -47.6% | -47.9% | -48.9% |
| Jul 31 | D. Boral Capital | Maintains | Buy → Buy | — | $3.15 | $1.99 | -36.8% | -41.6% | -48.9% | -47.6% | -47.9% | -48.9% |
| May 22 | Citigroup | Maintains | Neutral → Neutral | — | $3.14 | $3.09 | -1.6% | -0.6% | -1.0% | -1.6% | -5.7% | +1.9% |
| May 1 | D. Boral Capital | Maintains | Buy → Buy | — | $4.83 | $5.21 | +7.9% | -21.9% | -21.9% | -25.9% | -28.8% | -23.8% |
| May 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.83 | $5.21 | +7.9% | -21.9% | -21.9% | -25.9% | -28.8% | -23.8% |
| May 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.83 | $5.21 | +7.9% | -21.9% | -21.9% | -25.9% | -28.8% | -23.8% |
| Mar 11 | D. Boral Capital | Maintains | Buy → Buy | — | $7.22 | $7.22 | +0.0% | +1.1% | +1.4% | -2.4% | +4.2% | +7.9% |
| Feb 20 | Citigroup | Maintains | Neutral → Neutral | — | $6.64 | $7.60 | +14.5% | +32.2% | +34.9% | +34.3% | +30.7% | +38.9% |
| Dec 11 | Citigroup | Downgrade | Buy → Neutral | — | $6.58 | $6.17 | -6.2% | -2.9% | -8.1% | -7.3% | -5.8% | -6.8% |
| Dec 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $6.58 | $6.17 | -6.2% | -2.9% | -8.1% | -7.3% | -5.8% | -6.8% |
| Oct 31 | Stifel | Maintains | Buy → Buy | — | $6.79 | $6.75 | -0.6% | -8.0% | -7.7% | +4.9% | +4.7% | +13.5% |
| Aug 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $6.91 | $6.92 | +0.1% | -6.1% | -7.5% | -13.6% | -14.2% | -15.2% |
| Aug 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.91 | $6.92 | +0.1% | -6.1% | -7.5% | -13.6% | -14.2% | -15.2% |
| Aug 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.91 | $6.92 | +0.1% | -6.1% | -7.5% | -13.6% | -14.2% | -15.2% |
| May 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.72 | $9.98 | +29.3% | +21.5% | +27.2% | +20.2% | +23.4% | +14.1% |
| Apr 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.51 | $8.56 | +0.6% | -6.6% | -7.6% | -3.2% | -1.4% | +1.6% |
| Feb 23 | Citigroup | Maintains | Buy → Buy | — | $11.86 | $11.36 | -4.2% | -8.9% | -12.4% | -14.7% | -21.1% | -22.3% |
| Feb 23 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $11.86 | $11.36 | -4.2% | -8.9% | -12.4% | -14.7% | -21.1% | -22.3% |
| Feb 22 | Wells Fargo | Maintains | Overweight → Overweight | — | $14.50 | $14.20 | -2.1% | -18.2% | -25.4% | -28.3% | -30.2% | -35.4% |
| Feb 22 | Stifel | Maintains | Buy → Buy | — | $14.50 | $14.20 | -2.1% | -18.2% | -25.4% | -28.3% | -30.2% | -35.4% |
| Feb 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $14.50 | $14.20 | -2.1% | -18.2% | -25.4% | -28.3% | -30.2% | -35.4% |
| Oct 31 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.89 | $8.75 | +10.9% | +11.4% | +15.1% | +18.8% | +25.7% | +21.8% |
| Oct 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.89 | $8.75 | +10.9% | +11.4% | +15.1% | +18.8% | +25.7% | +21.8% |
| Aug 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $13.23 | $13.99 | +5.7% | +0.2% | +0.2% | -3.9% | -8.7% | -15.0% |
| Jul 11 | Citigroup | Maintains | Buy → Buy | — | $12.99 | $13.09 | +0.8% | +2.4% | +5.1% | +1.8% | +3.8% | +2.6% |
| May 3 | Citigroup | Maintains | Buy → Buy | — | $11.47 | $12.85 | +12.0% | +8.6% | +6.5% | +7.1% | +8.4% | +9.7% |
| May 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $11.47 | $12.85 | +12.0% | +8.6% | +6.5% | +7.1% | +8.4% | +9.7% |
| May 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.47 | $12.85 | +12.0% | +8.6% | +6.5% | +7.1% | +8.4% | +9.7% |
| Apr 3 | Citigroup | Maintains | Buy → Buy | — | $11.18 | $11.40 | +2.0% | -2.8% | -3.6% | -2.0% | +0.2% | -1.7% |
| Feb 27 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $10.37 | $11.15 | +7.5% | +6.0% | +8.3% | +10.7% | +9.8% | +14.4% |
| Feb 24 | Citigroup | Maintains | Buy → Buy | — | $10.53 | $10.41 | -1.1% | -1.5% | +4.4% | +6.6% | +9.0% | +8.2% |
| Feb 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.76 | $12.24 | +39.7% | +20.2% | +18.4% | +25.5% | +28.2% | +31.1% |
| Feb 23 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.76 | $12.24 | +39.7% | +20.2% | +18.4% | +25.5% | +28.2% | +31.1% |
| Jan 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $7.93 | $7.96 | +0.4% | -1.8% | +1.8% | +7.7% | +8.8% | +9.5% |
| Jan 3 | BofA Securities | Downgrade | Neutral → Underperform | — | $8.43 | $7.84 | -7.0% | -11.2% | -2.1% | -5.9% | -7.6% | -4.3% |
| Dec 12 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $5.88 | $6.25 | +6.3% | +8.0% | +18.2% | +16.3% | +21.4% | +25.7% |
| Dec 12 | Citigroup | Upgrade | Neutral → Buy | — | $5.88 | $6.25 | +6.3% | +8.0% | +18.2% | +16.3% | +21.4% | +25.7% |
| Nov 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.82 | $4.71 | -2.3% | +3.5% | +10.2% | +2.3% | +18.5% | +35.5% |
| Nov 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.34 | $10.00 | -19.0% | -60.9% | -59.6% | -57.0% | -60.0% | -53.7% |
No insider trades available.
8-K
Pulmonx Corporation -- 8-K Filing
Pulmonx Corporation reported Q1 2026 revenue of $20.6 million, down 9% year-over-year, indicating slowing growth momentum for the minimally invasive lung disease treatment company.
Apr 29
8-K · 1.01
! Medium
Pulmonx Corporation -- 8-K 1.01: Financing / Debt Agreement
Pulmonx Corporation secured a $60 million credit facility, providing additional liquidity to support operations and potentially fund strategic initiatives or debt refinancing.
Mar 5
8-K
Pulmonx Corporation -- 8-K Filing
Pulmonx strengthened its balance sheet in 2025 while refocusing investments on growth opportunities, demonstrating improved financial discipline as the minimally invasive lung disease treatment leader.
Mar 4
Data updated apr 25, 2026 8:05pm
· Source: massive.com